BPG is committed to discovery and dissemination of knowledge
Observational Study Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123962
Published online Nov 15, 2026. doi: 10.4251/wjgo.123962
Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma
Miao Hao, Chen-Rui Liu, Meng Zhang, Xia-Qing Zhou, Xin Zhang, Wen-Jun Wang, Yi-Kai Wang, Xiao-Li Jia, Ya-Ping Li, Shuang-Suo Dang, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
Zi-Cheng Jiang, Department of Infectious Diseases, Ankang Central Hospital, Ankang 725000, Shaanxi Province, China
Xiao-Hong Gao, Department of Infectious Diseases, Affiliated Hospital to Yan’an University, Yan’an 716000, Shaanxi Province, China
ORCID number: Xia-Qing Zhou (0009-0009-7562-8832); Xin Zhang (0000-0002-5966-0471); Wen-Jun Wang (0000-0001-9861-1763); Yi-Kai Wang (0000-0001-6709-1777); Xiao-Li Jia (0000-0001-8865-9771); Ya-Ping Li (0000-0002-0900-5559); Shuang-Suo Dang (0000-0003-0918-9535).
Co-corresponding authors: Ya-Ping Li and Shuang-Suo Dang.
Author contributions: Hao M conceived and designed the study, collected data, drafted the manuscript, planned the study, analyzed and interpreted data and performed statistical analysis; Liu CR, Zhang M, and Zhou XQ participated in analysis of clinical data, performed statistical analysis and drafted the manuscript; Jiang ZC and Gao XH participated in data collection and consultations in liver disease; Zhang X participated in critical revision of the manuscript and funding support; Wang YK participated in study design; Wang WJ and Jia XL participated in critical revision of the manuscript, consultations; Li YP and Dang SS participated in study conception and design, study supervision, data interpretation, manuscript editing and funding support, they contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
AI contribution statement: The authors declare that no AI tools were used in the development or writing of this manuscript and take full responsibility for its integrity, accuracy, and originality.
Supported by the National Key Research and Development Program of China 2023, No. 2023YFC2308105; and Natural Science Foundation of Shaanxi Province, No. 2023-JC-YB-770.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Second Affiliated Hospital of Xi’an Jiaotong University, approval No. 2022-051.
Informed consent statement: Informed consent is waived for this retrospective study, as it involves minimal risk and obtaining consent from all participants is impracticable due to the nature of existing data.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Data supporting the findings of this study are not publicly available due to privacy or ethical restrictions and are available upon request to the corresponding author.
Corresponding author: Shuang-Suo Dang, Professor, Department of Infectious Diseases, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 West 5th Road, Xi’an 710004, Shaanxi Province, China. dang212@126.com
Received: June 2, 2026
Revised: July 22, 2026
Accepted: September 1, 2026
Published online: November 15, 2026
Processing time: 156 Days and 10.8 Hours

Abstract
BACKGROUND

The proportion of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is as high as 85.69% among HCC patients in China. Current anti-HBV drugs include nucleos(t)ide analogs (NAs) and interferon (IFN).

AIM

To compare the impact of NAs and IFN therapy on the occurrence of HCC in patients at high risk of HBV-related HCC.

METHODS

We enrolled 368 patients with high risk of HBV-related HCC, and 120 received subcutaneous injections of IFN, with or without NAs, constituting the IFN group. The remaining 248 patients were assigned to the NAs group, and received treatment with NAs alone.

RESULTS

For patients with a high risk of HBV-related HCC, after a 5-year treatment period, HCC incidence in the IFN group was 2.54%, while the NAs group showed a significantly higher incidence of 25.74% (P < 0.001). After propensity score matching, HCC incidence in the IFN and NAs groups was 2.94% and 22.0%, respectively (P < 0.001).

CONCLUSION

IFN-based therapy, compared with NAs, significantly reduced the risk of HCC in patients with high risk of HBV-related HCC.

Key Words: Interferon; Nucleotides and nucleosides; Hepatocellular carcinoma; Hepatitis B virus; High-risk population for hepatocellular carcinoma; Chronic hepatitis B

Core Tip: Based on this observational study, we compared the incidence of hepatocellular carcinoma (HCC) in high-risk hepatitis B virus-related HCC patients receiving interferon vs nucleoside/nucleotide analogues. For hepatitis B virus-infected individuals with high-risk factors for HCC, interferon therapy before progression to decompensated cirrhosis helps reduce the risk of HCC.



INTRODUCTION

Recently, the disease burden of hepatocellular carcinoma (HCC) has surged in China, with approximately 410000 new cases and 391000 deaths in 2020, accounting for nearly half of the global burden[1]. The proportion of patients with hepatitis B virus (HBV)-related HCC is as high as 85.69% among HCC patients in China[2]. Although the popularization of hepatitis B vaccination has significantly reduced the number of new hepatitis B patients each year, there remains a large number of individuals with chronic hepatitis B (CHB) in China[3]. Most newly diagnosed cases of HCC are at an advanced stage, specifically Barcelona Clinic Liver Cancer stage C[4]. Therefore, early identification of HBV-related HCC high-risk groups coupled with individualized treatment and regular monitoring are important to reduce the incidence and burden of HCC.

Antiviral therapy for CHB reduces the risk of developing HCC by maximizing suppression of HBV replication and improving liver histopathology[5]. The Asia Pacific Association for the Study of Liver Diseases 2017 guidelines state that long-term and effective antiviral therapy in patients with CHB can be used as a secondary preventive measure for HBV-related HCC[6]. Current antiviral drugs include nucleos(t)ide analogs (NAs) and interferon (IFN)[7]. IFN-based treatment is superior to NA therapy in reducing HBV-related HCC in CHB patients[8]. However, several studies have shown that patients with CHB remain at risk of developing HCC after long-term antiviral therapy, and antiviral therapy can reduce but not eliminate the occurrence of HCC[9]. Several other studies have demonstrated that patients with high-risk factors for HCC, such as liver cirrhosis and a family history of HCC, have a significantly elevated risk of developing HCC compared with those with a common HBV infection[10-14]. For people at high-risk of HBV-related HCC, the application of IFN therapy is crucial to reduce the incidence of HCC. Therefore, in this study, we aimed to compare the effects of NAs and IFN on the risk of HCC in patients with high risk of HBV-related HCC. Additionally, the existing risk prediction models of HCC were validated by an external cohort and the main factors affecting the occurrence of HCC in this population were analyzed by logistic regression.

MATERIALS AND METHODS
Patients

This study collected patients with CHB who visited the Department of Infectious Diseases, the Second Affiliated Hospital of Xi’an Jiaotong University, Ankang Central Hospital, and the Affiliated Hospital of Yanan University from July 2011 to May 2023 in China. This study complied with clinical practice and the Declaration of Helsinki and was approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University, approval No. 2022-051. Written informed consent was waived by the Ethics Committee because this was a retrospective study using existing medical records and de-identified data, which involved no more than minimal risk to participants, and it was impracticable to obtain consent from all eligible individuals due to the large sample size and the difficulty of contacting patients retrospectively.

Inclusion criteria: (1) 18-65 years of age, regardless of gender; (2) CHB patients positive for hepatitis B surface antigen for > 6 months; and (3) High risk of HBV-related HCC (patients with any one of the following): Male ≥ 40 years, female ≥ 50 years; family history of HCC; alpha-fetoprotein (AFP) ≥ 7.0 ng/mL; liver nodules detected on imaging (defined as any focal lesion ≥ 5 mm detected on ultrasound, computed tomography, or magnetic resonance imaging, regardless of pathological nature); and compensated cirrhosis due to HBV (in accordance with the American Association for the Study of Liver Diseases 2018 hepatitis B guidance)[12].

Exclusion criteria: (1) Decompensated cirrhosis; (2) Study began at the time of diagnosis or within 6 months of being diagnosed with liver cancer or other systemic malignant tumors; (3) Hepatitis A virus, hepatitis C virus, hepatitis D virus, human immunodeficiency virus infection, or autoimmune hepatitis; and (4) Patients with severe cardiac, renal, and pulmonary insufficiency.

Study design

This was a multicenter retrospective study. Patients were assigned to the IFN group and NAs group according to their antiviral regimen. The IFN group received subcutaneous injections of peginterferon α-2a or peginterferon α-2b (180 μg/week), with or without NAs, for a total course of ≥ 24 weeks, constituting the IFN group. After completion of the 24-week IFN course, patients either continued IFN therapy (if clinically indicated) or switched to NAs maintenance therapy, based on the treating physician's clinical judgment. The duration of IFN treatment varied according to individual patient response and tolerability. Patients in the NAs group were treated with NAs alone. The NAs used in this study included entecavir (0.5 mg daily), tenofovir disoproxil fumarate (300 mg daily), lamivudine (300 mg daily) and tenofovir alafenamide (25 mg daily), etc, with the specific agent chosen according to the treating physician's discretion and patient characteristics.

The start of follow-up (time zero) was defined as the date of treatment initiation (first dose of IFN or first prescription of NAs) for all patients. For patients who had received prior antiviral therapy before enrollment, time zero was set as the date of enrollment into this study when the current treatment regimen was initiated. Patients who developed HCC within the first 6 months of follow-up were excluded to avoid reverse causality (as specified in the exclusion criteria). The endpoint was the occurrence of HCC. The design and patients enrolled in this study is shown in Figure 1.

Figure 1
Figure 1 Design and patients enrolled in this study. Reasons for exclusion during the 5-year follow-up included: Loss to follow-up (n = 42), self-discontinuation of treatment (n = 18), and development of decompensated cirrhosis (n = 9). HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAs: Nucleos(t)ide analogs; IFN: Interferon.
Study evaluation

Study assessments were based on the patients’ clinical history, laboratory findings, and imaging studies. The measures included clinical data at the start of and during treatment, including history of CHB, previous medication, family history of HCC, comorbidities (diabetes, fatty liver, etc.), and alcohol intake. Laboratory tests included white blood cell count, platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, HBV DNA, hepatitis B surface antigen, HBV e antigen, and AFP. Imaging examinations included liver B-ultrasound, computed tomography, and magnetic resonance imaging. Laboratory tests were performed at baseline and every 3-6 months during follow-up. Imaging examinations were performed at baseline and every 6-12 months, or more frequently if clinically indicated. The diagnosis of HCC is based on the “Diagnosis and Treatment Guidelines for Primary Liver Cancer (2019 Edition)” of China.

HCC risk scores and classification of different risk

In this study, the published Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV (REAL-B) model and the age-male-ALBI-platelets (aMAP) model were used to assess the risk of HCC in patients[15,16]. The REAL-B model incorporates the following variables: Age, sex, alcohol consumption, liver cirrhosis, platelet count, diabetes, and AFP[15]. The aMAP model incorporates: Age, sex, albumin-bilirubin grade, and platelet count[16]. Among them, the REAL-B model score 0-3 was classified as low risk, 4-7 as medium risk, and 8-13 as high risk. In the aMAP model, < 50 was classified as low risk, 50-60 as medium risk, and > 60 as high risk.

Statistical analysis

All patients who participated in this study were included in the final analysis. Statistical analysis was performed using SPSS version 27.0 and R version 4.3.3. The measurement data that conformed to normal distribution were expressed as the mean ± SD, the non-normally distributed data were expressed as the median and interquartile range, and the enumeration data were expressed as the rate. Propensity score matching (PSM) analysis was used to eliminate the influence of selection bias and patient baseline characteristics. By adjusting the baseline difference between the two groups to balance the influence of confounding factors, the specific matching ratio was 1:2 (IFN:NAs), with a caliper of 0.2 times the standard deviation of the propensity score. This resulted in 71 patients in the IFN group and 145 in the NAs group (actual matching ratio of 1:2.04, which approximates the intended 1:2 ratio). One-way analysis of variance was used to compare the means of measurement data with a normal distribution among multiple groups, and a nonparametric test was used to compare the means of measurement data with a non-normal distribution or unequal variance between groups. The Kaplan-Meier method was used to calculate the cumulative incidence of HCC after follow-up in both groups, and the last follow-up data were used for patients without HCC. Differences between groups were compared using the log-rank test. Univariate and multivariate Cox regression analyses were performed to assess the magnitude and significance of factors associated with hepatocarcinogenesis. All statistical tests were two-sided and P < 0.05 was considered statistically significant. This retrospective cohort study was reported in accordance with the STROBE statement.

RESULTS
Baseline characteristics of patients

Figure 1 presents the flow chart illustrating the selection process for participants in this study. Patients without high-risk factors for HCC, decompensated liver cirrhosis, combined, infection, self-discontinuation or loss to follow-up and patients who were diagnosed with HCC at the beginning were excluded from the analysis. After applying these exclusion criteria, this study finally included 368 patients, including 120 in the IFN group and 248 in the NAs group. Among the 120 patients in the IFN group, 39 (32.5%) received IFN monotherapy and 81 (67.5%) received IFN plus NAs combination therapy. The baseline characteristics of patients before and after PSM are shown in Table 1. After PSM, 216 patients were obtained, including 71 in the IFN group and 145 in the NAs group. There was no significant difference in baseline characteristics between the IFN and NAs groups (P > 0.05). It is important to acknowledge that before PSM, the NAs group had a higher proportion of patients with cirrhosis, elevated AFP, HBV e antigen positivity, and higher HBV DNA levels, indicating greater baseline disease severity. While PSM successfully balanced the measured covariates, residual confounding from unmeasured factors cannot be completely excluded. Nonetheless, the consistent protective effect of IFN observed across multiple sensitivity analyses supports the robustness of our findings.

Table 1 Baseline characteristics of interferon and nucleos(t)ide analogs groups before and after propensity score matching, n (%).
CharacterBefore PSM
After PSM
IFN group (n = 120)
NAs group (n = 248)
P value
SMD
IFN group (n = 71)
NAs group (n = 145)
P value
SMD
Sex--0.56---0.219-
Female29 (24.17)67 (27.02)-0.06715 (21.13)42 (28.97)--0.175
Male91 (75.83)181 (72.98)0.06756 (78.87)103 (71.03)-0.175
Age--0.359---0.68-
Male < 40 years or female < 50 years45 (37.50)81 (32.66)-0.129 (40.85)55 (37.93)-0.083
Male ≥ 40 years or female ≥ 50 years75 (62.50)167 (67.34)--0.142 (59.15)90 (62.07)--0.083
Family history of HCC--0.005---0.622-
No103 (85.83)180 (72.58)0.3856 (78.87)110 (75.86)-0.058
Yes17 (14.17)68 (27.42)-0.3815 (21.13)35 (24.14)--0.058
Liver cirrhosis< 0.001---0.267-
Non-cirrhosis80 (66.67)103 (41.53)-0.53339 (54.93)68 (46.90)-0.164
Compensatory cirrhosis40 (33.33)145 (58.47)--0.53332 (45.07)77 (53.10)--0.164
Alpha-fetoprotein ≥ 7.0 ng/mL--< 0.001---0.288-
No101 (84.17)127 (51.21)0.90353 (74.65)98 (67.59)-0.144
Yes19 (15.83)121 (48.79)-0.90318 (25.35)47 (32.41)--0.144
Liver nodules detected on imaging--0.939---0.536-
No89 (74.17)183 (73.79)-0.00957 (80.28)111 (76.55)-0.118
Yes31 (25.83)65 (26.21)--0.00914 (19.72)34 (23.45)--0.118
Diabetes--0.012---1-
No115 (95.83)217 (87.50)-0.41766 (92.96)136 (93.79)--0.04
Yes5 (4.17)31 (12.50)--0.4175 (7.04)9 (6.21)-0.04
Alcohol intake--0.304---0.536-
No94 (78.33)182 (73.39)0.1257 (80.28)111 (76.55)-0.118
Yes26 (21.67)66 (26.61)-0.1214 (19.72)34 (23.45)--0.118
Fatty liver--0.823---0.633-
No105 (87.50)219 (88.31)--0.02460 (84.51)126 (86.90)--0.078
Yes15 (12.50)29 (11.69)-0.02411 (15.49)19 (13.10)-0.078
Platelet count (× 109/L)174134.5< 0.0010.8261631490.1030.252
(146.00, 209.25)(89.00, 177.25)(139.00, 197.50)(108.00, 190.00)
HBsAg (IU/mL)378.491440.72< 0.001-1.043495.81818.420.088-0.262
(87.61, 1013.48)(559.95, 3118.72)(157.23, 1409.65)(425.93, 2236.81)
HBeAg--< 0.001---0.245-
Negative100 (83.33)133 (53.63)0.79753 (74.65)97 (66.90)-0.16
Positive20 (16.67)115 (46.37)-0.79718 (25.35)48 (33.10)--0.16
HBV DNA (lg IU/mL)0.00 (0.00, 2.01)2.90 (0.00, 5.30)< 0.001-1.0450.00 (0.00, 2.43)1.86 (0.00, 3.69)0.081-0.236
Comparison of the cumulative incidence of HCC in after antiviral therapy

At the end of the 5-year follow-up period, a significant disparity in the occurrence of HCC was observed between patients in the IFN and NAs groups. Among patients with a high risk of HBV-related HCC, after 5 years of treatment, the cumulative incidence of HCC in the IFN group remained at 2.54%, while the NAs group experienced a significantly higher cumulative incidence of 25.74% (P < 0.001) (Figure 2A). After PSM, 32 patients developed HCC during the 5-year follow-up period, including two in the IFN group and 30 in the NAs group. After PSM, the 5-year cumulative incidence of HCC in the IFN and NAs groups was 2.94% and 22.0%, respectively. There was a significant difference in the 5-year cumulative incidence of HCC between the two groups (P < 0.001) (Figure 2B).

Figure 2
Figure 2 Cumulative incidence of hepatocellular carcinoma over 5 years of follow-up in patients treated with nucleos(t)ide analogs vs interferon-based therapy. A: Before propensity score matching: The 5-year cumulative incidence was 25.74% (64/248) in the nucleos(t)ide analogs group and 2.54% (3/120) in the interferon group (P < 0.001, log-rank test); B: After propensity score matching (1:3 matching): The 5-year cumulative incidence was 22.0% (30/145) in the nucleos(t)ide analogs group and 2.94% (2/71) in the interferon group (P < 0.001, log-rank test). Shaded areas represent 95% confidence intervals. HCC: Hepatocellular carcinoma; NAs: Nucleos(t)ide analogs; IFN: Interferon.

Subgroup analysis based on five risk factors and whether antiviral therapy was first taken showed that male ≥ 40 years old or female ≥ 50 years old, no family history of HCC, with or without cirrhosis, no elevated AFP, no liver nodular, and prior antiviral therapy were significant differences in HCC occurrence after NAs treatment and IFN treatment (P < 0.05). However, the interaction between subgroups was not obvious (P < 0.05) (Figure 3).

Figure 3
Figure 3 Subgroup analysis forest map of hepatocellular carcinoma in a high risk population of hepatitis-B-virus-associated hepatocellular carcinoma. HCC: Hepatocellular carcinoma; NAs: Nucleos(t)ide analogs; IFN: Interferon; HR: Hazard ratio; CI: Confidence interval.
Univariate and multifactorial regression analysis of HCC

Univariate Cox regression analysis was performed on the factors that may affect the occurrence of HCC in patients with high-risk of HBV-related HCC. Age, family history of HCC, antiviral regimen, cirrhosis, and platelet count were correlated with the occurrence of HCC in patients with high risk of HBV-related HCC (P < 0.05). Multivariate Cox regression analysis suggested that male ≥ 40 years or female ≥ 50 years, and family history of HCC and cirrhosis were independent risk factors for HCC (P < 0.05). IFN treatment was an effective protective factor in patients with HCC (P < 0.001, hazard ratio = 0.12, 95% confidence interval: 0.04-0.39) (Table 2).

Table 2 Cox regression analysis of hepatocellular carcinoma occurrence in patients with high risk of hepatitis B virus-associated hepatocellular carcinoma.
Character
Univariate Cox regression
Multifactor Cox regression
P value
HR (95%CI)
P value
HR (95%CI)
Sex
Male-1.00 (reference)--
Female0.0731.77 (0.95–3.30)--
Age
Male < 40 years or female < 50 years-1.00 (reference)-1.00 (reference)
Male ≥ 40 years or female ≥ 50 years< 0.0013.43 (1.70-6.92)0.0052.76 (1.35-5.61)
Family history of HCC
No-1.00 (reference)-1.00 (reference)
Yes< 0.0012.32 (1.43-3.75)0.0221.76 (1.09-2.86)
Liver cirrhosis
Non-cirrhosis-1.00 (reference)-1.00 (reference)
Compensatory cirrhosis< 0.0013.91 (2.21-6.93)0.0092.27 (1.23-4.19)
-fetoprotein ≥ 7.0 ng/mL
No-1.00 (reference)--
Yes0.7481.08 (0.66-1.78)
Liver nodules detected on imaging
No-1.00 (reference)--
Yes0.3891.26 (0.75-2.12)--
Diabetes
No-1.00 (reference)--
Yes0.2161.56 (0.77-3.14)--
Alcohol intake
No-1.00 (reference)--
Yes0.7281.10 (0.65-1.86)--
Fatty liver
No-1.00 (reference)--
Yes0.9950.00 (0.00-infinity)--
Antiviral therapy
NAs treatment1.00 (reference)1.00 (reference)
Peg IFN-α treated with NAs alone or in combination< 0.0010.08 (0.02-0.25)< 0.0010.12 (0.04-0.39)
White blood cell count (× 109/L)0.8350.98 (0.85-1.14)--
Platelet count (× 109/L)< 0.0010.99 (0.99-0.99)0.2791.00 (0.99-1.00)
Glutamic-pyruvic transaminase (IU/L)0.5181.00 (1.00-1.01)--
Glutamic oxalacetic transaminase (IU/L)0.2131.00 (1.00-1.01)--
Albumin (g/L)0.5761.01 (0.96-1.07)--
Total bilirubin (μmol/L)0.4911.01 (0.98-1.04)--
Alkaline phosphatase (IU/L)0.3911.00 (1.00-1.01)--
Glutamyltranspeptidase (U/L)0.8561.00 (1.00-1.00)--
HBsAg (IU/mL)0.1311.00 (1.00-1.00)--
HBV DNA (lg IU/mL)0.4770.97 (0.88-1.06)--
HBeAg
Negative-1.00 (reference)--
Positive0.4100.81 (0.48-1.35)--
Abdominal lymph node enlargement
No-1.00 (reference)--
Yes0.6101.30 (0.47-3.57)--
Assessment of HCC risk stratification based on REAL-B and aMAP HCC models

The REAL-B and aMAP models were used to evaluate HCC risk stratification before and after treatment in the IFN and NAs groups (Figure 4). According to the REAL-B model prediction and evaluation, after treatment, the number of low-risk HCC patients in the IFN group increased by 15, while the number of low-risk patients in the NAs group increased by 62, and the number of high-risk patients decreased by 39. The overall risk stratification of HCC in the two groups after treatment decreased significantly compared with before (P < 0.05). After treatment, in the IFN group evaluated by the aMAP model, the number of medium-risk HCC patients increased by 10, and the number of low-risk patients decreased by 10. There was no significant difference in the overall HCC risk stratification in the IFN group before and after treatment (P = 0.141). Compared with before treatment, the number of high-risk HCC patients in the NAs group increased by 13, the number of medium-risk patients increased by 18, and the number of low-risk patients decreased by 31. Compared with before treatment, the overall risk stratification of HCC in the NAs group increased after treatment (P = 0.002).

Figure 4
Figure 4 Changes in hepatocellular carcinoma risk stratification in interferon group and nucleos(t)ide analogs group before and after treatment. A: Changes in the proportion of different risk groups before and after treatment based on Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for hepatitis B virus score; B: Changes in the number of different risk groups before and after treatment based on Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for hepatitis B virus score; C: Changes in the proportion of different risk groups before and after treatment based on age-male-ALBI-platelets score; D: Changes in the number of different risk groups before and after treatment based on age-male-ALBI-platelets score. NAs: Nucleos(t)ide analogs; IFN: Interferon; REAL-B: Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for hepatitis B virus; aMAP: Age-male-ALBI-platelets.
DISCUSSION
IFN therapy significantly reduces the risk of HCC

In this observational study, we compared the risk of HCC after IFN and NAs therapy in patients at high risk for HBV-related HCC. The results consistently indicated that the cumulative incidence of HCC was lower in the IFN than NAs group, regardless of whether PSM was performed. IFN is known to possess multiple beneficial effects, including antiviral, immunoregulatory, and antitumor properties[17-19]. Previous studies have confirmed that it can significantly reduce the occurrence of HCC in patients with CHB. A study conducted in Taiwan involving 330 CHB patients over 5 years found that the risk of HCC was lower in CHB patients treated with Peg-IFN compared to those treated with NAs alone[20]. Another study in Taiwan, with an average follow-up period of 6.8 years, observed a decrease in the cumulative incidence of HCC, particularly in patients with cirrhosis at baseline. However, there was no significant change in HCC incidence for patients without cirrhosis at baseline[21]. For patients with high risk factors for HCC, whether IFN therapy can achieve more benefits needs further exploration and verification. Our study focused on patients with a high risk of HCC. The 5-year cumulative incidence of HCC was 2.54% in the IFN group and 25.74% in the NAs group, and the 5-year cumulative incidence of HCC was reduced by 90.13% in the patients treated with IFN compared with NAs. To avoid the influence of previous antiviral status on the occurrence of HCC in patients, subgroup analysis was conducted between the newly treated patients and those who had been treated with NAs, and the results indicated that the cumulative incidence of HCC in 5 years was also significantly different between the two groups. In addition, stratified analysis of patients according to the five defined risk factors showed that the cumulative incidence of HCC was still significantly different between the two groups in most subgroups. The risk of HCC after IFN therapy is different in patients with and without cirrhosis compared with NAs therapy, but due to the higher overall risk in patients with cirrhosis, close monitoring is needed. In contrast, no significant difference was observed in the two subgroups with elevated AFP and imaging findings of liver nodules, which may be related to factors such as the small number of patients included in this subgroup. Alternatively, this subgroup of patients may have had other high-risk factors that had a greater impact on the development of HCC. Further more studies are needed, especially in subgroups with a low number of events (e.g., patients with abnormal AFP and patients with hepatic nodules), to confirm these outcome findings. Regardless, IFN has obvious advantages in reducing the occurrence of HCC in people at high risk of HBV-related HCC.

Identification of people at high risk for HBV-associated HCC helps stratified management

We focused on the high-risk population for HBV-related HCC due to the significant prevalence of HBV infection among HCC patients in China, accounting for > 80% of cases[22]. Different guidelines provide guidance on the definition of high-risk groups for HCC. Combining the guidelines of various countries and regions, it can be clearly seen that cirrhosis and HBV/hepatitis C virus infection are the most recognized risk factors for HCC[6,22-24]. In addition, genetic factors, such as having a family history of cirrhosis or HCC, greatly increase the risk of developing HCC[10,11,25]. Imaging detection of liver nodules and abnormal HCC-specific serological markers such as AFP are early warning signs of HCC worthy of special attention[26,27]. Based on these guidelines, this study proposed a definition for patients with high risk of HBV-related HCC.

Decompensated cirrhosis is a contraindication to the use of IFN; therefore, only patients with compensated cirrhosis were included in our study to reduce bias in patients with decompensated cirrhosis. Compared with the cumulative incidence of HCC after 5 years of NAs treatment, the risk of HCC in patients with a high risk of HBV-related HCC was significantly higher (25.74%) than that in ordinary CHB patients (previously reported to be 9.1%)[9]. The cumulative incidence of HCC after IFN treatment in the high-risk group of HBV-related HCC was 2.54%, demonstrating a significant reduction in HCC risk with IFN therapy.

We also analyzed the factors associated with HCC development in all patients, and univariate Cox results showed that age, family history of HCC, cirrhosis, antiviral regimen, and platelet count were associated with HCC development in patients with high risk of HBV-associated HCC. Multivariate Cox regression analysis suggested that male ≥ 40 years or female ≥ 50 years, and family history of HCC and cirrhosis were independent risk factors for HCC, which was consistent with the results of previous studies. Antiviral therapy with IFN is an effective protective factor for HCC, which confirms the conclusion that IFN can significantly reduce the cumulative incidence of HCC in patients with high risk of HBV-related HCC.

Different HCC prediction models have confirmed that IFN therapy can reduce the risk of HCC

The HCC risk prediction model constructed based on patient demographic information, medical history data, and laboratory test results is a more individualized tool for evaluating HCC risk and performing risk stratification. To date, there is a variety of HCC risk prediction models for patients with different races and different etiologies of liver disease. In recent years, with the popularization of HBV antiviral therapy, a variety of HCC risk prediction models have been designed for patients with CHB treated with antiviral therapy[28,29]. Wu et al[30] conducted a systematic evaluation and external validation of 14 HCC risk prediction models. In patients with CHB, the REAL-B model, which is based on age, sex, alcohol consumption, liver cirrhosis, platelet count, diabetes and AFP, showed the best performance[15,30]. In this study, the risk stratification of HCC before and after treatment in the two groups was predicted and evaluated according to the REAL-B model. The overall risk stratification of HCC in the IFN and NAs groups was lower than before, and the difference was significant; that is, both IFN and NAs reduced the risk of HCC in patients with high risk of HBV-related HCC. Fan et al[16] developed an aMAP model involving age, male sex, albumin-bilirubin and platelet count. This model can better assess the risk of HCC in patients with chronic liver disease of different etiologies and races. According to the aMAP model, there was no significant difference in the overall HCC risk stratification in the IFN group before and after treatment, while the overall HCC risk stratification in the NAs group was higher than before treatment, and the medium-high risk stratification had a higher risk of HCC; that is, the overall HCC risk in the NAs group was higher than before. Compared with NAs therapy, IFN can delay the increase in HCC in patients with high risk of HBV-related HCC caused by aging and prolonged CHB, thus reducing the occurrence of HCC. Based on the REAL-B and aMAP models, compared with NAs, IFN can better reduce the occurrence of HCC in patients with high risk of HBV-related HCC.

Study limitations

This study had some limitations. Firstly, the follow-up period for most patients was limited to 5 years. The occurrence of HCC is a gradual and long-term process; therefore, it is essential to continue follow-up and analysis of patients in the future to obtain 10-year and longer-term data on the cumulative incidence of HCC. Secondly, after PSM, in both the cirrhosis and noncirrhosis subgroups, no significant difference in the 3-year and 5-year cumulative incidence of HCC was observed between the NAs and IFN groups. This may be attributed to the larger sample size, making the differences less apparent. To strengthen the findings, future research will include more patients with high risk of HBV-related HCC and continue long-term follow-up. Thirdly, since decompensated cirrhosis is an absolute contraindication to the use of IFN therapy, this study did not include patients diagnosed with decompensated cirrhosis at the beginning of the study. However, these patients may have a higher cumulative incidence of HCC, and whether IFN therapy can be used for patients with reversal to compensated cirrhosis requires further research in the future. Despite these limitations, the study provides valuable insights into the effects of IFN therapy on the occurrence of HCC in patients with high risk of HBV-related HCC. To build upon these findings and strengthen the evidence base, future studies with extended follow-up periods and inclusion of a broader range of patient populations are warranted.

CONCLUSION

In conclusion, our study demonstrates that, compared with NAs, IFN therapy can significantly reduce the occurrence of HCC in patients with high risk of HBV-related HCC.

ACKNOWLEDGEMENTS

Thanks to the patients and their families for their contribution to this study.

References
1.  Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 76817]  [Cited by in RCA: 71803]  [Article Influence: 14360.6]  [Reference Citation Analysis (115)]
2.  Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. Clin Mol Hepatol. 2023;29:206-216.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 139]  [Cited by in RCA: 146]  [Article Influence: 48.7]  [Reference Citation Analysis (2)]
3.  Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1323]  [Reference Citation Analysis (0)]
4.  Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1057]  [Cited by in RCA: 1090]  [Article Influence: 99.1]  [Reference Citation Analysis (35)]
5.  Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33:e00046-e00019.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 457]  [Cited by in RCA: 380]  [Article Influence: 63.3]  [Reference Citation Analysis (1)]
6.  Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1808]  [Cited by in RCA: 1808]  [Article Influence: 200.9]  [Reference Citation Analysis (23)]
7.  Lin YJ, Sun FF, Zeng Z, Bi XY, Yang L, Li MH, Xie Y. Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report. Viral Immunol. 2022;35:71-75.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2]  [Cited by in RCA: 8]  [Article Influence: 1.6]  [Reference Citation Analysis (4)]
8.  Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z, Zhou T, Lu J, Liu Y, Guo Q, Chen R, Zhou H, Xiang X, Cai W, Wang H, Bao S, Xu Y, Gui H, Xie Q. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther. 2018;18:1085-1094.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 36]  [Cited by in RCA: 35]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
9.  Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY, Chen CH. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020;14:513-520.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 8]  [Cited by in RCA: 15]  [Article Influence: 2.5]  [Reference Citation Analysis (1)]
10.  Huang X, Wang H, Zhang W, Gu E. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment. Eur J Gastroenterol Hepatol. 2022;34:546-552.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 3]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
11.  Yang Y, Wu QJ, Xie L, Chow WH, Rothman N, Li HL, Gao YT, Zheng W, Shu XO, Xiang YB. Prospective cohort studies of association between family history of liver cancer and risk of liver cancer. Int J Cancer. 2014;135:1605-1614.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 15]  [Cited by in RCA: 22]  [Article Influence: 1.8]  [Reference Citation Analysis (2)]
12.  Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3558]  [Cited by in RCA: 3413]  [Article Influence: 426.6]  [Reference Citation Analysis (24)]
13.  Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1979]  [Cited by in RCA: 1812]  [Article Influence: 82.4]  [Reference Citation Analysis (17)]
14.  Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, Jacobson IM. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol. 2022;20:1766-1775.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 52]  [Cited by in RCA: 54]  [Article Influence: 13.5]  [Reference Citation Analysis (0)]
15.  Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. J Infect Dis. 2020;221:389-399.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 67]  [Cited by in RCA: 86]  [Article Influence: 14.3]  [Reference Citation Analysis (5)]
16.  Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen HLA, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73:1368-1378.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 298]  [Cited by in RCA: 306]  [Article Influence: 51.0]  [Reference Citation Analysis (17)]
17.  Suslov A, Boldanova T, Wang X, Wieland S, Heim MH. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. Gastroenterology. 2018;154:1778-1790.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 162]  [Cited by in RCA: 153]  [Article Influence: 19.1]  [Reference Citation Analysis (0)]
18.  Wu ZQ, Tan L, Gan WQ, Mo ZS, Chen DB, Wang PP, Zhao QY, Xie DY, Gao ZL. The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α. Ann Transl Med. 2021;9:414.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 9]  [Reference Citation Analysis (0)]
19.  Li Q, Sun B, Zhuo Y, Jiang Z, Li R, Lin C, Jin Y, Gao Y, Wang D. Interferon and interferon-stimulated genes in HBV treatment. Front Immunol. 2022;13:1034968.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 51]  [Cited by in RCA: 52]  [Article Influence: 13.0]  [Reference Citation Analysis (3)]
20.  Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. J Infect Dis. 2016;213:966-974.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 74]  [Cited by in RCA: 75]  [Article Influence: 7.5]  [Reference Citation Analysis (8)]
21.  Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45-52.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 254]  [Cited by in RCA: 240]  [Article Influence: 12.6]  [Reference Citation Analysis (1)]
22.  Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book. 2018;38:262-279.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 184]  [Cited by in RCA: 175]  [Article Influence: 21.9]  [Reference Citation Analysis (2)]
23.  Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10:181-223.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 566]  [Cited by in RCA: 586]  [Article Influence: 117.2]  [Reference Citation Analysis (12)]
24.  European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 6763]  [Cited by in RCA: 6754]  [Article Influence: 844.3]  [Reference Citation Analysis (19)]
25.  Chang X, Li Y, Sun C, Li X, Du W, Shang Q, Song L, Long Q, Li Q, Liu H, Wang J, Yu Z, Li J, Xiao G, Li L, Chen L, Tan L, Chen Y, Yang Y. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2023;58:481-493.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 6]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
26.  Mei Q, Yu M, Chen Q. Clinical value of contrast-enhanced ultrasound in early diagnosis of small hepatocellular carcinoma (≤ 2 cm). World J Clin Cases. 2022;10:8525-8534.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in CrossRef: 4]  [Cited by in RCA: 7]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
27.  Turshudzhyan A, Wu GY. Persistently Rising Alpha-fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Review. J Clin Transl Hepatol. 2022;10:159-163.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 33]  [Cited by in RCA: 34]  [Article Influence: 8.5]  [Reference Citation Analysis (1)]
28.  Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800-806.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 467]  [Cited by in RCA: 471]  [Article Influence: 47.1]  [Reference Citation Analysis (14)]
29.  Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69:278-285.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 133]  [Cited by in RCA: 151]  [Article Influence: 18.9]  [Reference Citation Analysis (4)]
30.  Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang HI. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clin Gastroenterol Hepatol. 2021;19:2499-2513.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 37]  [Cited by in RCA: 44]  [Article Influence: 8.8]  [Reference Citation Analysis (1)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Gastroenterology & Hepatology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade A, Grade B, Grade B, Grade B

Novelty: Grade A, Grade B, Grade B, Grade B

Creativity or innovation: Grade A, Grade B, Grade B, Grade B

Scientific significance: Grade A, Grade A, Grade B, Grade B

P-Reviewer: Gutiérrez-Cuevas J, Full Professor, PhD, Mexico; Jiang X, Assistant Professor, PhD, China; Yi CH, PhD, China S-Editor: Bai Y L-Editor: A P-Editor: Zhao YQ

Write to the Help Desk